It is reported that a study conducted by Italian researchers showed that adding colchicine to conventional treatment can prevent recurrent episodes of pericarditis.
The colchicine treatment for recurrent pericarditis (CORP) study used this drug during the first recurrence of pericarditis, Dr. Massimo Imazio (Mary Victoria Hospital, Turin, Italy) at the 2011 Annual Meeting of the European Society of Cardiology (ESC) The latest clinical trials released the results of the study. The results have also been published online in Annals of Internal Medicine.
He commented that colchicine appears to be a safe and low-cost drug for rapid symptom relief, can improve remission rates within 1 week, and reduce recurrence during the first episode of recurrent pericarditis.
Dr. Andre Keren, a reviewer of the study (Hebrew University Hospital, Jerusalem, Israel) pointed out that relapse is a thorny and common complication of acute pericarditis. Both CORP and early single-center studies (CORE) showed that low doses of colchicine Can effectively prevent the recurrence of the disease. Keren urged that the time has come to use colchicine more freely.
Colchicine halvees the recurrence rate of pericarditis. Imazio said that about one-third of pericarditis patients will relapse. CORP is the first multi-center, double-blind, randomized trial of colchicine for secondary prevention of pericarditis. Early CORE study results.
The time for more liberal use of colchicine has arrived. In the trial, 120 patients with first recurrence of pericarditis were randomized to placebo or low doses of colchicine (patients over 70 kilograms, 1 mg, twice daily, 24 hours). Followed by 0.5mg, twice daily, 6 months) plus conventional treatment - 800mg to 1000mg of aspirin or ibuprofen 600mg orally, every 8 hours, 7 to 10 days as the first choice, or prednisone 0.2 ~ 0.5mg/kg /day, four weeks as the second choice.
The primary endpoint was the relapse rate at 18 months. Secondary endpoints included persistence of symptoms at 72 hours, remission rate at 1 month, number of relapses, time to subsequent relapse, disease-related hospitalization, pericardial tamponade, and constrictive pericarditis.
Colchicine halved the rate of recurrence - 24% of patients taking colchicine relapsed, 55% of patients taking placebo (relative risk reduction of 56%; P <0.001), compared with placebo, taking autumn The number of secondary endpoints of patients with narcissus was also significantly reduced.
He added that the dose of colchicine used in this experiment was safe, and there was no difference in adverse events between the colchicine group and the placebo group.
He said that the results support the use of low-dose colchicine as a first-line adjuvant treatment for standard treatment of recurrent pericarditis and said that the results of the trial were impressive.
However, he pointed out that the results of CORP targeted to the specific people involved in the experiment - the first relapse of adult pericarditis patients, except for patients with bacterial or neoplastic pericarditis and contraindications to colchicine - and therefore can not be applied to other situations Or patient populations such as children. In addition, he also pointed out that the use of colchicine for the treatment of pericarditis is an indication outside the label.
Last year at the ESC conference, Imazio reported that colchicine prevented post-cardiac surgeries from post-operative heart failure.
Imazio has no conflicts of interest. Keren has no conflicts of interest.
The colchicine treatment for recurrent pericarditis (CORP) study used this drug during the first recurrence of pericarditis, Dr. Massimo Imazio (Mary Victoria Hospital, Turin, Italy) at the 2011 Annual Meeting of the European Society of Cardiology (ESC) The latest clinical trials released the results of the study. The results have also been published online in Annals of Internal Medicine.
He commented that colchicine appears to be a safe and low-cost drug for rapid symptom relief, can improve remission rates within 1 week, and reduce recurrence during the first episode of recurrent pericarditis.
Dr. Andre Keren, a reviewer of the study (Hebrew University Hospital, Jerusalem, Israel) pointed out that relapse is a thorny and common complication of acute pericarditis. Both CORP and early single-center studies (CORE) showed that low doses of colchicine Can effectively prevent the recurrence of the disease. Keren urged that the time has come to use colchicine more freely.
Colchicine halvees the recurrence rate of pericarditis. Imazio said that about one-third of pericarditis patients will relapse. CORP is the first multi-center, double-blind, randomized trial of colchicine for secondary prevention of pericarditis. Early CORE study results.
The time for more liberal use of colchicine has arrived. In the trial, 120 patients with first recurrence of pericarditis were randomized to placebo or low doses of colchicine (patients over 70 kilograms, 1 mg, twice daily, 24 hours). Followed by 0.5mg, twice daily, 6 months) plus conventional treatment - 800mg to 1000mg of aspirin or ibuprofen 600mg orally, every 8 hours, 7 to 10 days as the first choice, or prednisone 0.2 ~ 0.5mg/kg /day, four weeks as the second choice.
The primary endpoint was the relapse rate at 18 months. Secondary endpoints included persistence of symptoms at 72 hours, remission rate at 1 month, number of relapses, time to subsequent relapse, disease-related hospitalization, pericardial tamponade, and constrictive pericarditis.
Colchicine halved the rate of recurrence - 24% of patients taking colchicine relapsed, 55% of patients taking placebo (relative risk reduction of 56%; P <0.001), compared with placebo, taking autumn The number of secondary endpoints of patients with narcissus was also significantly reduced.
He added that the dose of colchicine used in this experiment was safe, and there was no difference in adverse events between the colchicine group and the placebo group.
He said that the results support the use of low-dose colchicine as a first-line adjuvant treatment for standard treatment of recurrent pericarditis and said that the results of the trial were impressive.
However, he pointed out that the results of CORP targeted to the specific people involved in the experiment - the first relapse of adult pericarditis patients, except for patients with bacterial or neoplastic pericarditis and contraindications to colchicine - and therefore can not be applied to other situations Or patient populations such as children. In addition, he also pointed out that the use of colchicine for the treatment of pericarditis is an indication outside the label.
Last year at the ESC conference, Imazio reported that colchicine prevented post-cardiac surgeries from post-operative heart failure.
Imazio has no conflicts of interest. Keren has no conflicts of interest.
Disposable Reinforced Surgical Gown
CE Certified Disposable Reinforced Surgical Gown:
Surgical gown is made from high quality composite material. It is breathable, water resistant, and anti-static.
Color: Blue
Size: L/XL or custmozied
Weight: 41gsm
Fabric Type: SMS
Samples Free samples for 3-5 working days
Features Long sleeve, Round neck(Velcro), Rib cuff, double waist tie, Ultrasonic seam
Application Used to prevent infection between patients and medical staff during procedures and other traumatic examinations
Reinforced Disposable Gown,Level 3 Surgical Gown,Disposable Reinforced Gown,Non Sterile Surgical Gowns
Suzhou JaneE Medical Technology Co., Ltd. , https://www.janeemedical.com